Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00773409 · ClinicalTrials.gov registry record

Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)

A clinical trial of Renal Insufficiency, sponsored by Bracco Diagnostics.

Completed
Registry status
405
Enrollment target
1
Study location

NCT00773409: Completed study of Renal Insufficiency, sponsored by Bracco Diagnostics.

NCT00773409 is a study of Renal Insufficiency that has completed, run by Bracco Diagnostics. The registered enrollment target is 405 participants, above the 83-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (388% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00773409, a study of Renal Insufficiency, has completed, sponsored by Bracco Diagnostics.

COMPLETED
Registry status
405 participants
Enrollment target
1
Study location

Study Summary

The objective of this long term study is to prospectively evaluate the incidence of NSF in patients with severe CKD or kidney failure including patients undergoing dialysis (stages 4 and 5 i.e., with an eGFR below 30)who have not had exposure to a GBCA within 10 years prior to enrollment.

Conditions Studied

Study Locations (1)

New Jersey

  • Bracco Diagnostics Inc. - Princeton

Trial Details

FieldValue
Enrollment Target 405 participants
Start Date 2008-10
Est. Completion 2012-07
Bracco Diagnostics

37 total trials

What the finished NCT00773409 record still lists

NCT00773409 is an observational study that tracks outcomes without assigning an intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (388% higher).

The record links to 1 condition, with Renal Insufficiency appearing as the primary indexed condition, and to 0 interventions.

NCT00773409 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00773409 about?

NCT00773409 is a clinical study titled "Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)". The objective of this long term study is to prospectively evaluate the incidence of NSF in patients with severe CKD or kidney failure including patients undergoing dialysis (stages 4 and 5 i.e., with an eGFR below 30)who have not had exposure to a GBCA within 10 years prior to enrollment.

What is the current status of trial NCT00773409?

This trial is currently completed. The enrollment target is 405 participants. The study started on 2008-10. Estimated completion is 2012-07.

What conditions does trial NCT00773409 study?

This clinical trial studies the following conditions: Renal Insufficiency.

Who is sponsoring clinical trial NCT00773409?

This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00773409 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Renal Insufficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00773409's enrollment target sits among peer trials

405 2nd of 22 the highest of 22 other Renal Insufficiency trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Renal Insufficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05576350 · 405 participants · NA

    TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

  • NCT07066657 · 405 participants · Phase 1

    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

  • NCT06223360 · 406 participants · Phase 2

    A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

  • NCT06411769 · 406 participants · NA

    Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00773409, the US trial registry maintained by the National Library of Medicine. NCT00773409 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.